205 related articles for article (PubMed ID: 24446122)
1. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.
Bergmann AK; Schneppenheim S; Seifert M; Betts MJ; Haake A; Lopez C; Maria Murga Penas E; Vater I; Jayne S; Dyer MJ; Schrappe M; Dührsen U; Ammerpohl O; Russell RB; Küppers R; Dürig J; Siebert R
Genes Chromosomes Cancer; 2014 Apr; 53(4):309-16. PubMed ID: 24446122
[TBL] [Abstract][Full Text] [Related]
2. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.
López C; Bergmann AK; Paul U; Murga Penas EM; Nagel I; Betts MJ; Johansson P; Ritgen M; Baumann T; Aymerich M; Jayne S; Russell RB; Campo E; Dyer MJ; Dürig J; Siebert R
Br J Haematol; 2016 Apr; 173(2):265-73. PubMed ID: 26917488
[TBL] [Abstract][Full Text] [Related]
3. T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.
Hu Z; Medeiros LJ; Xu M; Yuan J; Peker D; Shao L; Tang Z; Mai B; Thakral B; Rios A; Hu S; Wang W
Am J Clin Pathol; 2023 Apr; 159(4):325-336. PubMed ID: 36883805
[TBL] [Abstract][Full Text] [Related]
4. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker.
Stengel A; Kern W; Zenger M; Perglerová K; Schnittger S; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2016 Jan; 55(1):82-94. PubMed ID: 26493028
[TBL] [Abstract][Full Text] [Related]
5. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.
Kiel MJ; Velusamy T; Rolland D; Sahasrabuddhe AA; Chung F; Bailey NG; Schrader A; Li B; Li JZ; Ozel AB; Betz BL; Miranda RN; Medeiros LJ; Zhao L; Herling M; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Aug; 124(9):1460-72. PubMed ID: 24825865
[TBL] [Abstract][Full Text] [Related]
6. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia.
Bellanger D; Jacquemin V; Chopin M; Pierron G; Bernard OA; Ghysdael J; Stern MH
Leukemia; 2014 Feb; 28(2):417-9. PubMed ID: 24048415
[No Abstract] [Full Text] [Related]
7. Translocations t(X;14)(q28;q11) and t(Y;14)(q12;q11) in T-cell prolymphocytic leukemia.
de Oliveira FM; Tone LG; Simões BP; Rego EM; Marinato AF; Jácomo RH; Falcão RP
Int J Lab Hematol; 2009 Aug; 31(4):453-6. PubMed ID: 18294235
[TBL] [Abstract][Full Text] [Related]
8. Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia.
Patil P; Cieslak A; Bernhart SH; Toprak UH; Wagener R; López C; Wiehle L; Bens S; Altmüller J; Franitza M; Scholz I; Jayne S; Ahearne MJ; Scheffold A; Jebaraj BMC; Schneider C; Costa D; Braun T; Schrader A; Campo E; Dyer MJS; Nürnberg P; Dürig J; Johansson P; Böttcher S; Schlesner M; Herling M; Stilgenbauer S; Macintyre E; Siebert R
Genes Chromosomes Cancer; 2020 Apr; 59(4):261-267. PubMed ID: 31677197
[TBL] [Abstract][Full Text] [Related]
9. Comparison of karyotyping,
Sun Y; Tang G; Hu Z; Thakral B; Miranda RN; Medeiros LJ; Wang SA
J Clin Pathol; 2018 Apr; 71(4):309-315. PubMed ID: 28821581
[TBL] [Abstract][Full Text] [Related]
10. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia.
Soulier J; Pierron G; Vecchione D; Garand R; Brizard F; Sigaux F; Stern MH; Aurias A
Genes Chromosomes Cancer; 2001 Jul; 31(3):248-54. PubMed ID: 11391795
[TBL] [Abstract][Full Text] [Related]
11. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
Gomez-Arteaga A; Margolskee E; Wei MT; van Besien K; Inghirami G; Horwitz S
Leuk Lymphoma; 2019 Jul; 60(7):1626-1631. PubMed ID: 30997845
[No Abstract] [Full Text] [Related]
12. T cell prolymphocytic leukemia with new chromosome rearrangements.
Zver S; Kokalj Vokac N; Zagradisnik B; Erjavec A; Zagorac A; Zupan IP; Cernelc P
Acta Haematol; 2004; 111(3):168-70. PubMed ID: 15034240
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.
Sato T; Toki T; Kanezaki R; Xu G; Terui K; Kanegane H; Miura M; Adachi S; Migita M; Morinaga S; Nakano T; Endo M; Kojima S; Kiyoi H; Mano H; Ito E
Br J Haematol; 2008 May; 141(5):681-8. PubMed ID: 18397343
[TBL] [Abstract][Full Text] [Related]
14. JAK3 in clear cell renal cell carcinoma: mutational screening and clinical implications.
de Martino M; Gigante M; Cormio L; Prattichizzo C; Cavalcanti E; Gigante M; Ariano V; Netti GS; Montemurno E; Mancini V; Battaglia M; Gesualdo L; Carrieri G; Ranieri E
Urol Oncol; 2013 Aug; 31(6):930-7. PubMed ID: 21868263
[TBL] [Abstract][Full Text] [Related]
15. Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
Degryse S; Bornschein S; de Bock CE; Leroy E; Vanden Bempt M; Demeyer S; Jacobs K; Geerdens E; Gielen O; Soulier J; Harrison CJ; Constantinescu SN; Cools J
Blood; 2018 Jan; 131(4):421-425. PubMed ID: 29187379
[TBL] [Abstract][Full Text] [Related]
16. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
Koo GC; Tan SY; Tang T; Poon SL; Allen GE; Tan L; Chong SC; Ong WS; Tay K; Tao M; Quek R; Loong S; Yeoh KW; Yap SP; Lee KA; Lim LC; Tan D; Goh C; Cutcutache I; Yu W; Ng CC; Rajasegaran V; Heng HL; Gan A; Ong CK; Rozen S; Tan P; Teh BT; Lim ST
Cancer Discov; 2012 Jul; 2(7):591-7. PubMed ID: 22705984
[TBL] [Abstract][Full Text] [Related]
17. PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression.
Yuan S; Wang X; Hou S; Guo T; Lan Y; Yang S; Zhao F; Gao J; Wang Y; Chu Y; Shi J; Cheng T; Yuan W
Leukemia; 2022 Feb; 36(2):370-382. PubMed ID: 34465864
[TBL] [Abstract][Full Text] [Related]
18. Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv(14)(q11q32).
Dürig J; Bug S; Klein-Hitpass L; Boes T; Jöns T; Martin-Subero JI; Harder L; Baudis M; Dührsen U; Siebert R
Leukemia; 2007 Oct; 21(10):2153-63. PubMed ID: 17713554
[TBL] [Abstract][Full Text] [Related]
19. Activated janus kinase 3 expression not by activating mutations identified in natural killer/T-cell lymphoma.
Guo Y; Arakawa F; Miyoshi H; Niino D; Kawano R; Ohshima K
Pathol Int; 2014 Jun; 64(6):263-6. PubMed ID: 24965108
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.
Jeong EG; Kim MS; Nam HK; Min CK; Lee S; Chung YJ; Yoo NJ; Lee SH
Clin Cancer Res; 2008 Jun; 14(12):3716-21. PubMed ID: 18559588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]